The FMTVDM FRONTIER™ Sovereign Standard™ Series
- Richard M Fleming, PhD, MD, JD
- 17 hours ago
- 4 min read
Part I: The Cost of Misinformation: Why Blood Tests and Diet Fads Keep Failing to Diagnose Heart Disease — and Why FMTVDM Ends the Guesswork
For more than half a century, the world has been told that heart disease can be detected — and prevented — by watching cholesterol levels, flipping the food pyramid every decade, and trusting that “normal” blood tests mean “normal” coronary arteries.
This belief has cost trillions of dollars, misdirected entire national health systems, and most tragically, cost millions of lives.
The FMTVDM measurable‑era has now made one fact unavoidable:
Blood tests do not diagnose coronary artery disease (CAD). They never have.
Losing weight, in and of itself, does not reverse CAD - it never has.
Only FMTVDM, the patented quantitative method measuring the InflammoThrombotic Immunologic Response (ITIR) Disease (ITIRD), known as CAD, can determine whether CAD is present, how severe it is, and whether treatment is actually working.
This is not opinion. It is published, reproducible, multicenter, international evidence.
1. The Evidence the World Has Ignored
1.1. The Angiology Study: Blood Tests Do Not Predict Coronary Blood Flow
In Angiology (2008), Fleming & Harrington evaluated 120 men and women, measuring 11 markers of Inflammation, Thrombosis and Immunologic change — including total cholesterol, LDL, HDL, triglycerides, CRP, IL‑6, fibrinogen, homocysteine, and more.
The findings were unequivocal:
Baseline blood tests had no diagnostic relationship to coronary ischemia
Changes in blood tests did not reliably predict changes in coronary blood flow
Only quantified myocardial perfusion imaging (MPI) — the precursor to FMTVDM — identified true physiologic disease
This single study should have changed clinical practice worldwide. Instead, the system doubled down on cholesterol panels and “risk factor management,” while CAD continued to grow as the #1 killer.
2. The Multicenter International Trial: FMTVDM Works Everywhere
The 2018 multicenter clinical trial (Fleming et al., J Nucl Med Radiat Ther) confirmed what the FMTVDM measurable‑era now demands:
Seven centers across the U.S. and Asia reproduced the same quantitative results
401 patients were evaluated using FMTVDM with A.I.2‑derived QCFR/FCFR®
Correlation with quantitative coronary angiography was R² = 0.87582 (p < 0.0001)
Accuracy was independent of isotope, camera type, manufacturer, or
stressor/enhancing agent(s) employed
This is what reproducibility looks like.
This is what science looks like.
This is what the FMTVDM measurable‑era requires.
3. Dr. Arif Sheikh’s Review: Nuclear Medicine Has Been Waiting for This
In his 2018 review, Dr. Arif Sheikh — a respected nuclear medicine physician — made the case plainly:
Qualitative imaging misses disease
SUVs and semi‑quantitative methods are inconsistent and often misleading
FMTVDM provides TRUE quantification, not virtual estimation
FMTVDM detects disease that conventional imaging calls “normal”
His conclusion was unmistakable: FMTVDM is the first method since 1925 to return nuclear cardiology to its quantitative roots — and surpass them.
4. The 20/20 Episode: When the Public Saw the Truth
The ABC 20/20 investigative segment (https://rumble.com/vpjdgp-2020-episode-on-my-work.html) documented what patients already knew:
People with “normal” blood tests were still having heart attacks
Patients told they were “fine” were actually living and dying with severe CAD
FMTVDM identified disease that every other test missed
Blood tests looking for "inflammation" (ie. CRP) while helpful, were later shown in 2008 (see " #1. The Evidence the World Has Ignored" above) to not be as helpful as once thought and only now was the world learning about the early development and use of FMTVDM.
This was more than journalism.
It was a warning.
5. The Color Graphic: The Visual Proof
The graphic demonstrates what the data has shown for decades:
Changes in weight do not diagnose CAD
Changes in cholesterol do not diagnose CAD
Changes in CRP, IL‑6, fibrinogen, or homocysteine do not diagnose CAD
Only changes in measured ITIRD — quantified by FMTVDM — reveal true improvement or worsening
This is why patients “doing everything right” still die.
They are being advised and measured with the wrong tools.
6. Why the Food Pyramid Keeps Flipping — and Why It Doesn’t Matter
Every 5-years, the U.S. rewrites its dietary guidelines:
Low‑fat
High‑carb
Low‑carb
Mediterranean
Plant‑based
Keto
Each time, the public is told: “This is the answer.”
But without measuring ITIRD with FMTVDM, no dietary intervention can be evaluated honestly.
FMTVDM ends the guessing.
It shows what works — and what doesn’t — for each individual patient.
7. The Measurable‑Era Standard: FMTVDM
FMTVDM is the only patented method that:
Quantifies regional blood flow
Measures metabolism
Detects inflammation, thrombosis and immune response
Calculates QCFR/FCFR®
Accurately measures and tracks treatment response over time
Works with SPECT, PET, planar imaging, and probes
This is not a “new test.”
It is the new standard — the first quantitative standard in the history of nuclear cardiology.
8. The Cost of Continued Guessing and Misinformation
Every year, billions are spent on:
Unnecessary procedures
Ineffective medications
Misleading blood tests
Diet fads with no measurable outcomes
And every year, people die because their disease was never measured.
FMTVDM changes that.
9. What Comes Next — The Three‑Part Series
This is Part I of the FMTVDM FRONTIER™ series providing just some of the evidence that this patented test—FMTVDM with its A.I.2 proprietary equations and algorithms—is the paradigm shift Dr. Sheikh declared "we've been waiting for."
Part I — Heart Disease: How FMTVDM ends the era of qualitative guessing and replaces it with measurable ITIRD quantification.
Part II — Cancer: How FMTVDM‑BEST® quantifies tumor vascularity and metabolism, revealing what mammography, MRI, and PET miss.
Part III — Infection: How FMTVDM quantifies inflammatory and infectious processes — including those invisible to conventional imaging.
The FMTVDM measurable‑era has begun.
The world now has a choice:
Continue guessing — or begin measuring.
Comments